Safety of benznidazole use in the treatment of chronic Chagas' disease
Open Access
- 13 February 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (5), 1261-1266
- https://doi.org/10.1093/jac/dks027
Abstract
To assess the safety of benznidazole use in adult patients with chronic Chagas' disease. The Naranjo algorithm was applied to classify the causality of adverse drug reactions (ADRs). In total, 190 patients were treated with benznidazole over a period of 4–180 days (mean 58.90 ± 36.54 days) with a dose of 50–500 mg/day (221.33 ± 57.16 mg/day). Of the 190 patients treated, 93 had ADRs and 59 of these interrupted treatment. There was a higher incidence of ADRs among female and young adult patients. There was a higher incidence of ADRs during the first 30 days of treatment. Interruption of treatment was more frequent in women. Among the patients who interrupted treatment, 39 had mild ADRs, 19 had moderate ADRs and 1 had a severe ADR. There were no interruptions in treatment for 97 patients without ADRs. The survival curves indicated that the time until interruption of treatment in patients with moderate and severe ADRs was lower than in patients with mild or no ADRs. The most frequent disorders were in the skin (26.3%), gastrointestinal system (9.5%) and nervous system (5.3%). The Naranjo algorithm was a useful tool to reduce the underreporting of ADRs. Events were common, but were associated with low morbidity and were reversible upon discontinuation of drug treatment. Moreover, there were no fatal events; therefore, benznidazole treatment was considered safe.Keywords
This publication has 20 references indexed in Scilit:
- I Diretriz Latino-Americana para o diagnóstico e tratamento da cardiopatia chagásica: resumo executivoArquivos Brasileiros de Cardiologia, 2011
- Chagas disease: A Latin American health problem becoming a world health problemActa Tropica, 2010
- Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysisJournal of Antimicrobial Chemotherapy, 2009
- Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy.Memórias do Instituto Oswaldo Cruz, 2009
- Side effects of benznidazole as treatment in chronic Chagas disease: fears and realitiesExpert Review of Anti-infective Therapy, 2009
- Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)American Heart Journal, 2008
- Chemotherapy of trypanosomiases and leishmaniasisTrends in Parasitology, 2005
- Histoplasmoma pulmonar no Rio Grande do SulRevista da Sociedade Brasileira de Medicina Tropical, 2005
- Long term evaluation of etiological treatment of chagas disease with benznidazole.Revista do Instituto de Medicina Tropical de São Paulo, 2002
- Clinical and epidemiological aspects of Chagas diseaseThe Lancet Infectious Diseases, 2001